Executive record

Nachi Subramanian

Director at Atara Biotherapeutics, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:nachi-subramanianVersion: public-0As of: 2026-09-30

Not yet claimed11 published Claims4 sources
  • Director

Key Claims

Biography

Mr. Subramanian has served as a Board member since May 2025, appointed in connection with Redmile Group's investment in the Company. He is a Managing Director at Redmile Group, a healthcare-focused investment firm, and previously spent fourteen years at J.P. Morgan in senior roles across Private Markets and Global Cash Equities. He began his career in Institutional Equities at Bear Stearns.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Managing Director · Organization not publishedATRA DEF 14A director slate

Claims

Conflicts and accountability

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ATRA DEF 14A director slate

    sec filing · Source published: Apr 24, 2026 · Retrieved: May 1, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 1, 2026
    • Board role: Board role: Director · Claim reviewed: May 1, 2026
    • Committee assignments: Committee assignments: Nominating/Governance · Claim reviewed: May 1, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 1, 2026
    • Executive company: Executive at Redmile Group · Claim reviewed: May 1, 2026
    • Executive title: Executive title: Managing Director · Claim reviewed: May 1, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 1, 2026

  2. Atara Biotherapeutics, Inc. director board source

    sec filing · Source published: Apr 24, 2026 · Retrieved: May 3, 2026

    Supports 3 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Atara Biotherapeutics, Inc. · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  3. Open source

    sec proxy · Source published: Apr 24, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Atara Biotherapeutics, Inc. · Claim reviewed: May 1, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Atara Biotherapeutics, Inc. · Claim reviewed: May 3, 2026